Abstract: The invention provides an immunizing agent or preparation e.g. a vaccine for parenteral administration comprising particles of coalesced and covalently interlinked physiologically compatible proteinaceous molecules and, entrapped in these particles, an immunogen adapted to be released by the gradual proteolysis of the particles and, when so released, being of sufficient size to elicit an immuno response to characteristic immunogenic determinants of the immunogen. The proteinaceous molecules are preferably homotypic for the animal to be immunized. Preferably, the particles or molecules carrying the immunogenic determinants are crosslinked to the proteinaceous molecules.

Abstract: The invention relates to acino-fetal differentiation proteins associated with cancer of the pancreas, these proteins being mannoside-containing glycoproteins of average apparent molecular mass chosen from: 120 KD, 94 KD and 58 KD.The invention also relates to a method for preparing these proteins, an antiserum against these proteins and the method for preparation thereof, monoclonal antibodies against these proteins and the method for preparation thereof, and compositions for diagnostic or therapeutic use containing these proteins or antibodies.

Abstract: Novel cannabinol derivatives are provided which can be used in improved immunoassays for the detection in blood or urine samples of cannabinol metabolites.

Abstract: The invention relates to a method of immunoassay for monoamines (molecules having a primary or secondary amine function) comprising chemical quantitative conversion of such amines into derivatives of higher molecular weight, which thereafter are brought into competition with radioactive analogous, or analogous carrying a tracer, for fixation to an antibody capable of recognizing all of them.

Abstract: An in vitro diagnostic method for detecting the presence in a patient of cancer cells or other cells producing mucin antigens comprises the step of testing a sample of a physiological fluid, particularly a sample of blood, blood serum or blood plasma, taken from the patient to detect the presence of small intestine mucin antigen (SIMA) and/or large intestine mucin antigen (LIMA) in the sample. An in vitro diagnostic kit is also disclosed.

Abstract: Derivatives of propranolol which have the following structure: ##STR1## where R is X--(CH.sub.2).sub.n --O, X is NH.sub.2 or COOH, n is 1,2,3,4, or 5, provided that when n is 1, X must be COOH, and R is attached in the 4',5',6',7' or 8' position. The compounds are useful in immunoassay applications to (1) conjugate to a protein carrier in order to prepare antibodies to propranolol and (2) to conjugate to a tracer moiety such as a radiolabeled ligand, an enzyme, an enzyme substrate or a fluorescent dye.

Abstract: Multiple sclerosis (MS) is diagnosed by determining with a quantitative immunoassay the quantity of free kappa light chains in the cerebrospinal fluid of a patient. The immunoassay is preferably a radioimmunoassay. In carrying out the immunoassay, the free kappa light chains are combined with antiserum specific thereto. This method of diagnosing MS has high sensitivity in distinguishing between normal patients and patients affected with MS.

Abstract: A biochemical reagent system and methods for preparing and using same, as well as diagnostics utilizing the reagent system are disclosed. The biochemical reagent system comprises a receptor raised in an animal host to plasminogen activator inhibitor, and indicating means. The receptor binds to a specific plasminogen activator inhibitor that itself binds to tissue-type or urokinase-type plasminogen activators.

Abstract: An improvement in an assay method which relies on the detection of a labeled, solubilized specific binding complex is achieved by linking the label to a component of the complex through a bond cleavable under conditions compatible with the assay and with the complex in solution.

Abstract: A method of forming a therapeutic or diagnostic agent labeled with a radioactive metal ion, which comprises: contacting an unlabeled therapeutic or diagnostic agent, consisting of a substantially non-metal chelating portion and a chelating portion capable of chelating with the radioactive metal ion, with an ion transfer material having the radioactive metal ion bound thereto and having a binding affinity for the radioactive metal less than the binding affinity of the chelating portion for the radioactive metal ion, wherein prior to contacting the chelating portion is unchelated or is chelated with a second metal having a binding affinity with the chelating portion less than the binding affinity of the radioactive metal ion, whereby a radiolabeled therapeutic or diagnostic agent is formed by the contacting, and separating the radiolabeled therapeutic or diagnostic agent from the ion transfer material, is disclosed along with various components and kits useful in practicing this method and several variations th

Abstract: A process for predicting the sensitivity of cells, e.g., tumor cells, to the effects of tumor necrosis factor or lymphotoxin involving ascertaining the binding of the tumor necrosis factor or lymphotoxin to the cells, i.e., measuring the number of receptors on the cells.

Abstract: A digoxin derivative/immunogenic protein conjugate is disclosed which has the carbohydrate moiety of digoxin intact. Antibodies raised against this conjugate show minimal cross-reactivity to digoxin metabolites enabling the use as an antibody in the diagnostic analysis for digoxin when measured in the presence of its metabolites found in serum isolated from a human.

Abstract: An immunochemical assay, and compositions used therein, to determine the presence and/or amount of human chromogranin A, which is useful in diagnosis of disease associated with alterations in sympathoadrenal activity.

Abstract: Monoclonal antibodies specific to Neisseria gonorrhoeae lipopolysaccharide components having no cross-reactivity with N. meningitidis have been produced and found useful in the diagnosis of the presence of N. gonorrhoeae.

Abstract: A method of measuring the concentration of a free ligand in a biological fluid containing the free ligand and ligand bound to endogenous binding agent, by the steps of(a) mixing a sample of the fluid with an analogue of the ligand, a specific binder with which the free ligand and the ligand analogue bind, and an exogenous binding agent which binds the ligand analogue but not the ligand, either the ligand analogue or the specific binder being labelled,(b) incubating the resulting mixture,(c) determining either the amount of the labelled analogue bound or the amount of labelled specific binder bound, or not bound, to the ligand analogue, and(d) correlating the determined amount to the amount of free ligand present in the sample.The method is useful to measure concentration of free thyroid hormones and other hormones in body fluids, employing antibodies specific to the ligand analogue as the exogenous binding agents.

Abstract: A first glycoprotein having a molecular weight of approximately 61,000-68,000 daltons in the MJ, C5-MJ, C91 PL or HUT-102 cell lines, of which 46,000 to 48,000 is the unglycosylated moiety, is obtained from cells infected with human T cell leukemia virus. A second glycoprotein having a molecular weight of approximately 45,000-52,000 daltons is also obtained from such cells and is in large part identical to the NH.sub.2 -terminal end of the first glycoprotein. The presence, in a biological specimen, of antibody to the antigenic determinant of either of these proteins is indicative of the presence of cells infected by human T cell leukemia virus. An assay for the antibody is a useful diagnostic procedure for determining such infection in biologial specimens.

Abstract: A method is disclosed for the determination of human serum factors which are specific for human carcinomata antigens, in which method the serum of a patient with a carcinoma is incubated with CEA that has been radioactively labeled and anti-goat immunoglobulin serum in toto or depleted of the cross-reaction capacity for human IgA, IgG and IgM is added, then the whole mass is incubated and centrifugated, the supernatant is decanted and the precipitate is counted with a gamma counter. These specific serum factors are employed as a marker of primitive tumoral forms.

Abstract: An immunoassay is disclosed which measures the concentration of cyclosporin analytes in sample fluids. Also disclosed is radioiodinated cyclosporin having a specific activity greater than 50 ulCi/ug and fluorescent labeled cyclosporin, both of which is cross-reactive with cyclosporin analytes.

Abstract: Hybridoma for production of monoclonal antibody to an antigen found on the peptide fragment of the B.beta. chain of human fibrinogen or fibrin I containing amino acid residues 1-42. The hybridoma is formed by fusing an animal myeloma cell, e.g., a mouse myeloma cell, with a splenocyte from an animal, e.g., a mouse, immunized with an NH.sub.2 -terminal of human fibrinogen or fibrin I. Hybridoma for production of monoclonal antibody to an antigen found on the peptide fragment of the B.beta. chain of human fibrin II containing amino acid residues 15-42. The hybridoma is formed by fusing an animal, e.g., mouse myeloma cell with a splenocyte from an animal, e.g., mouse, immunized with a NH.sub.2 -terminal of human fibrin II. Diagnostic and therapeutic uses of the monoclonal antibodies are also disclosed.

Abstract: Early pregnancy can be determined by detection of a protein in milk, which protein is associated with the placental membrane. The protein is characterized by having an approximate molecular weight of 47,000 to 53,000 and an isoelectric point of from about 4.0-4.4.

Abstract: Certain substituted adenosines have been found to selectively occupy A.sub.1 adenosine receptors found in animal brain tissues.

Abstract: A novel method for the determination of protecting anti-HBV immunoglobulins is based on the use of two different HBsAg reagents: one insolubilized and having the antigenic type AX and one labelled and having the antigenic type AY, wherein A represents the epitope or epitopes which are common to all HBsAg serotyes, wherein X and Y both represent combinations of the epitopes which are not common to all HBsAg serotypes, and where the combinations X and Y have no epitopes in common.

Abstract: The invention relates to monoclonal anti-idiotypic antibodies to human anti-DNA antibodies. Monoclonal, anti-idiotypic antibodies are produced using hybridoma technology. The antibodies are used as diagnostic reagents in methods to determine the presence of anti-native DNA antibodies in serum from patients suspected of having systemic lupus erythematosus.

Abstract: The invention relates to monoclonal anti-idiotypic antibodies to human anti-DNA antibodies. Monoclonal, anti-idiotypic antibodies are produced using hybridoma technology. The antibodies are used as diagnostic reagents in methods to determine the presence of anti-native DNA antibodies in serum from patients suspected of having systemic lupus erythematosus, and as therapeutic reagents in methods to remove the anti-native DNA antibodies from the serum of patients with systemic lupus erythematosus.

Abstract: A method for detecting a minute quantity of an inorganic or organic target molecule by combining it with a composition of a detecting agent for the target molecule which carries, by direct or indirect means, a visualization polymer. The visualization polymer is composed of multiple units of a visualization monomer which are covalently linked together directly or indirectly covalently linked together by coupling agents which bond to chemical groups of the monomer. The monomer may be an enzyme, a tagged polypeptide, a tagged polyol, a tagged polyolefin or a tagged carbohydrate. The detecting agent may be an antibody, an enzyme, a lectin, strand of a DNA receptor protein, avidin, streptavidin and the like. The visualization polymer produces a high degree of amplification for the detection of the target molecule.

Abstract: A procedure for detecting malignancy includes culturing human colon tumor cells in a capillary system. A rabbit is immunized with byproducts of the culture. An antibody produced in the rabbit is labeled with .sup.125 I using lactoperoxidase according to a known method. Blood samples are drawn from a being to be tested. The drawn blood is processed to produce serum. The immune complexes are removed from the serum with purified protein A from the Staphlococcus Aureus Cowan strain. The removed immunocomplexes are dissociated with 0.2M glycene/HCl pH 2.8. The labeled antibody is combined with the antigen component of the immunocomplex to produce a new labeled immunocomplex. The newly formed immunocomplex is precipitated with PEG 6000. The newly formed labeled immunocomplexes are counted in a gamma auto counter.

Abstract: A substituted aldosterone of the formula: ##STR1## wherein either one of R.sup.1 and R.sup.2 is hydrogen and the other is --S(CH.sub.2).sub.m COR.sup.3 or --OCO(CH.sub.2).sub.n COR.sup.3, provided that when R.sup.1 is hydrogen, R.sup.2 is --S(CH.sub.2).sub.m COR.sup.3 or --OCO(CH.sub.2).sub.n COR.sup.3 and when R.sup.2 is hydrogen, R.sup.1 is --S(CH.sub.2).sub.m COR.sup.3 ; m being an integer from 1 to 3, n being an integer from 1 to 5 and R.sup.3 being hydroxyl, lower alkoxy or a residue of tyramine, tyrosine lower alkyl ester, histamine, histidine, 7-aminoheptanoyltyrosine lower alkyl ester or .beta.-D-galactosidase as optionally iodinated, or its (18-20)-acetal 20,21-ketonide, which is useful as the reagent in determination of aldosterones by radioimmunoassay or enzyme immunoassay.

Abstract: Compounds useful in a simultaneous multiple assay for analytes such as steroids, proteins, peptides, carbohydrates or drugs. The compound or compounds are prepared by labelling an individual analyte with a radioisotope through a chelating agent to form a coordinated compound. The assay uses one or more chelated labelled analytes with one or more labelled analytes wherein each radioisotope is different.

Abstract: Bifunctional aromatic compounds are employed as rigid coupling compounds for coupling one organic compound to another. For example, paranitrophenylisocyanate may be employed as a coupling compound for coupling thyroxine to a fluorescent dye to form a tracer for use in an assay.

Abstract: A peptide of the formula ##STR1## wherein A is Tyr or Phe, or a pharmaceutically acceptable salt thereof, is useful for the diagnosis of parathyroid gland function. When A is Tyr, the peptide can be labelled with iodine-125 without losing its PTH activity and without undergoing oxidation upon storage.

Abstract: There are provided bifunctional chelating agents, which are analogues of EDTA, conjugates of same with a variety of haptens and conjugates of such conjugates with haptens with certain metals, forming metal complexes. The metal complexes have a variety of uses, among these various assays for the determination of haptens and macromolecules. There is also provided a process for the production of the above. There are provided radioimmunoassays based on the above conjugates with metal cations.

Abstract: Derivatives of propranolol which have the following structure: ##STR1## where R is X--(CH.sub.2).sub.n --O, X is NH.sub.2 or COOH, n is 1,2,3,4, or 5, provided that when n is 1, X must be COOH, and R is attached in the 4', 5', 6', 7' or 8' position. The compounds are useful in immunoassay applications to (1) conjugate to a protein carrier in order to prepare antibodies to propranolol and (2) to conjugate to a tracer moiety such as a radiolabeled ligand, an enzyme, an enzyme substrate or a fluorescent dye.

Abstract: Monoclonal antibodies specific for thyroxine (T.sub.4) are produced by two new and separate hybridoma cell lines. Combinations of the monoclonal antibodies from the two cell lines are used in an immunoassay for T.sub.4 of high accuracy over the range of T.sub.4 concentrations encountered in serum samples.

Abstract: Radioimmunossays for the quantitation of serum thymic factor (FTS), a thymic peptide hormone, are disclosed. Each assay employs an antibody specific for FTS, the monoclonal antibody or the antibody from the antiserum of a host animal; synthetic FTS or FTS analogue as the hormone standard; and a radiolabeled FTS analogue as the tracer. Also disclosed is a method of treating serum or other biological fluid prior to assay of FTS to remove interfering substances.

Abstract: An improved immunoassay method, reagent means, test kit, and test device for determining an iodothyronine, e.g., thyroxine (T-4), in a biological fluid, usually serum or plasma, wherein 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid (HMS), or a salt thereof, is employed as a blocking agent for the binding of iodothyronines to thyroxine binding protein (TBP). The present invention is particularly advantageous as applied to homogeneous competitive binding iodothyronine immunoassays employing labels which are participants in enzyme-catalyzed reactions. Such labels include enzyme substrates, coenzymes, enzyme inhibitors, enzyme prosthetic groups, and enzymes.

Abstract: A composition having a protein binding solid support onto which is bound a mixture of antigens and antibodies which are both bound to the solid support individually and are not present in the form of an immune complex.

Abstract: This invention is directed to AUT-PK 500, a novel autophosphorylating protein kinase, to the purification and characterization of AUT-PK 500 from rat adrenocortical carcinoma, to the use of AUT-PK 500 as a marker for neoplasia cells, and to a radioimmunoassay for detecting AUT-PK 500 in neoplasia cells.

Abstract: A sensitive and specific radioimmunoassay is developed for L-hyoscyamine ulting from atropine administration with which a concentration as low as 25 pg/ml using 0.1 ml of sample can be measured without the need for extraction. Specificity studies indicate that an antibody according to this invention has high specific recognition of L-hyoscyamine with only about 37% cross reaction with the D-hyoscyamine enantiomer of atropine. The antibody is produced from an immunogen having conjugated at least 42 and preferably 45 L-hyoscyamine-p-aminobenzoic acid haptenic molecules per molecule of bovine serum albumin. An antibody according to this invention can be used with a dilution titer as high as 1:2000.

Abstract: The present invention concerns an autologous precipitating antibody and the gp70 pigment-associated antigen on melanoma cells which it recognizes. The antibody is useful in detecting pigmented melanoma cells in excised specimen, serum or urine.

Abstract: Monoclonal antibody reactive with SCC cells and unreactive with human neuroblastoma cells, human squamous cell carcinoma cells, and human large-cell undifferentiated lung carcinoma cells.

Abstract: A peptide having the formula ##STR1## is synthesized. The peptide is conjugated, e.g., with bis-diazotized benzidine, at its C-terminus to a carrier, such as bovine serum albumin, to form a synthetic antigen useful for inducing antibody production in a host animal. The antiserum obtained from the host animal is free of cross-reactivity with other pituitary substances and thus particularly advantageous for assay purposes. The peptide, whether unlabeled or labeled with radioactive iodine on the tyrosine moiety, has an affinity to antiserum raised against the conjugate similar to the affinity of natural hPRL to the antiserum. The synthetic peptide is used in radioimmunoassays where the labeled peptide competes for the binding sites in the antiserum with unknown concentrations of hPRL in biological samples.

Abstract: A method for detecting the presence of Mycobacteria in a fluid or tissue which comprises mixing the fluid or tissue containing a secretory product of Mycobacteria with a complex of a tracer-containing molecule and a binding macromolecule having reversible binding affinity for the tracer-containing molecule detecting the tracer-containing molecule, wherein the tracer-containing molecule is a charcoal-adsorbable protein from Mycobacterium tuberculosis which has a molecular weight of 20,000-30,000 and which is immunochemically stable from 4.degree. C. to 250.degree. C. and has a pH range from 3.0 to 9.0. The method is particularly applicable to the detection of infectious tuberculosis in humans and determining the antibiotic sensitivity of infecting Mycobacteria.

Abstract: Method for the diagnosis of cancer tumors which comprises determining the concentration of oncofetal urine peptide in the blood serum or the urine of the patient. The oncofetal urine peptide is immunochemically identifiable by means of an antiserum which is produced by the immunization of purified oncofetal urine peptide. The purification method has the following steps:(a) concentrating urine peptides from cancer patients by means of dialyzation and lyophilization;(b) separating the urine peptides having a molecular weight of 4,000 to 10,000 by means of gel filtration to achieve a peptide fraction;(c) concentrating of the peptide fraction through lyophilization;(d) subjecting the peptide fraction to ion exchange chromatography by using SP-Sephadex, gradient elution at pH 4 to 5, ion strength 0.1 to 0.5 mol/l;(e) subjecting the treated peptide fraction to high Pressure Liquid Chromatography using a reverse phase column and eluation in a gradient containing phosphate buffer 10 mmol/l pH 6.

Abstract: Early pregnancy can be determined by detection of a protein in serum, which protein is associated with the placental membrane. The protein is characterized by having an approximate molecular weight of 47,000 to 53,000 and an isoelectric point of from about 4.0-4.4.

Abstract: A radioimmunoassay for the polypeptide thymic hormone thymosin .beta..sub.4 is described. The assay employs a radiolabelled Tyr-C13-thymosin .beta..sub.4 -analogue as probe and a thymosin .beta..sub.4 antibody.

Abstract: Novel radioactive stilbene derivatives marked with iodine 125 or 131 of the formula ##STR1## wherein each A and B are both hydrogen or together form a double bond and R is the remainder of amino acid of the formula R--NH.sub.2 or a derivative thereof possessing an iodine acceptor group and marked with iodine 125 or 131 and their preparation and antigens obtained therefrom and a process for preparing said antigens.

Abstract: A process for preparing a stable receptor preparation suitable for the quantitative determination of substances able to bind to cerebral receptors in which a brain or brain-region material is homogenized with an aqueous solution of an inert substance soluble in water; the formed homogenizate is centrifuged at an acceleration of 800 to 110 g for 8 to 20 minutes to form a supernatant; the brain or brain-region material is isolated from the supernatant by centrifuging the supernatant at an acceleration of 18,000 to 22,000 g for 10 to 20 minutes, the thus-obtained solid substance is rehomogenized in distilled water; the homogenizate is frozen and then thawed and thereafter centrifuged at an acceleration of 7000 to 9000 g for 5-15 minutes; the supernatant is isolated, centrifuged at an acceleration of 35,000 to 45,000 g for 20 to 30 minutes; the obtained solid substance is washed with an aqueous buffer solution of a pH value between 6 and 8, and a suspension consisting of the solid substance and the washing liquid

Abstract: Method of separating A.sub.14 -.sup.125 I-insulin from heterogeneously labeled insulin molecules for biological studies which involves iodating insulin in a controlled manner, selectively absorbing the insulin from the iodination procedure in a tightly packed bed of octadecylsilane bonded to silica employing reverse phase liquid chromatography principles, thereafter eluting large and small radioactive and nonradioactive materials such as damaged insulin, various contaminants and polar materials from the bed with dilute trifluoroacetic acid, thereafter eluting the intact .sup.125 I-insulin from the bed with a mixture of acetonitrile and dilute trifluoroacetic acid and then separating the A.sub.14 -insulin by high performance liquid chromatography or ion exchange chromatography.

Abstract: Preparations useful in the diagnosis of infectious mononucleosis are disclosed. Horse and sheep erythrocytes are purified and essentially homogenous glycoproteins are extracted. The purified glycoproteins are useful as antigens in testing for the presence of the heterophile antibodies of infectious mononucleosis and in the preparation of reagents for the enumeration of rosetting lymphocytes without having to have available fresh sheep blood.

Abstract: A rapid, sensitive, and specific method for diagnosing Legionnaires' disease through the detection of antigens excreted by the patient and a method for preparing anti-Legionella immunoglobulin G for use in such diagnostic method.